Congenital atrophic dermatofibrosarcoma protuberans detected by COL1A1-PDGFB rearrangement by Maki Makino et al.
CASE REPORT Open Access
Congenital atrophic dermatofibrosarcoma
protuberans detected by COL1A1-PDGFB
rearrangement
Maki Makino1, Shunsuke Sasaoka1, Gen Nakanishi2, Eiichi Makino1,3* and Wataru Fujimoto1
Abstract
Background: Atrophic variant of dermatofibrosarcoma protuberans (DFSP) is a distinct form of DFSP.
Case presentation: Here, we report the case of a 19-year-old woman with a small congenital atrophic plaque on the
right precordium. The lesion remained atrophic for more than 10 years. Several years earlier, a portion of the plaque
became tuberous and enlarged. Physical examination revealed a 25 × 30 mm erythematous atrophic plaque
surrounded by three hard, smooth, and orange-colored nodules of varying sizes on the right precordium, along
with visible subcutaneous adipose tissue and cutaneous veins. Biopsy of the nodule and atrophic plaque revealed
dense proliferation of spindle-shaped tumor cells from the dermis to the subcutaneous adipose tissue, and positive
immunostaining for CD34 and vimentin in addition to negative staining for factor XIIIa and α-smooth muscle actin.
Reverse transcription polymerase chain reaction (RT-PCR) of the tumor tissue revealed the presence of a COL1A1-PDGFB
fusion gene. Thus, congenital atrophic dermatofibrosarcoma protuberans was diagnosed. No metastasis to the lungs or
regional lymph nodes was found on magnetic resonance imaging. Wide local excision and split-thickness skin grafting
was performed and neither recurrence nor metastasis has been observed for 5 years and 8 months since the surgery.
Conclusion: This case indicates that a congenital atrophic lesion could represent a quiescent phase of DFSP.
Awareness of this rare condition can aid with early diagnosis and thereby improve the prognosis of DFSP.
Background
Dermatofibrosarcoma protuberans (DFSP) is a locally
aggressive mesenchymal neoplasm of the skin character-
ized by high rates of local recurrence after surgical exci-
sion but a low risk of metastasis to the lymph nodes and
other organs [1]. DFSP is cytogenetically featured by
t(17;22)(q22;q13) translocation, resulting in the fusion of
the collagen type I α1-chain (COL1A1) gene with the
platelet-derived growth factor β-chain (PDGFB) gene
[1–5]. The COL1A1-PDGFB fusion gene is detected in
>90 % of cases of DFSP [1, 4] and represents a very use-
ful tool for the differential diagnosis of DFSP with other
benign/malignant neoplasms.
The DFSP lesion is usually present as a tumor that pro-
trudes above the surface of the skin. Atrophic DFSP, a re-
cently identified rare variant of DFSP, appears as a
depressed plaque [6–10]. In this variant, the fusion gene
has been detected in three reported cases [2, 5, 11]. This
rare variant is considered an early stage of DFSP [8]. Here
we describe the case of a 19-year-old woman with con-
genital atrophic DFSP on the right precordium. The lesion
was recognized at birth and remained atrophic for more
than 10 years before developing into a tumor. The pres-
ence of a COL1A1(exon25)-PDGFB(exon2) fusion gene
detected by polymerase chain reaction (PCR) confirmed
the diagnosis of congenital atrophic DFSP. Recognition of
this rare atrophic variant of DFSP can lead to early diag-
nosis and to improve the disease prognosis.
The goal of this report is to highlight the potential
clinical variability in the presentation of congenital DFSP
and the importance of considering this diagnosis in
pediatric patients with atypical cutaneous or subcutane-
ous tumors.
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Case presentation
A 19-year-old woman presented with an atrophic plaque
and small nodules on the right precordium. The atro-
phic plaque was present at birth and remained quiescent
for more than 10 years. Several years prior, a portion of
the plaque became tuberous and enlarged, and the patient
presented to our institution. She was otherwise healthy
and had no systemic symptoms and no remarkable family
history. On initial examination, a 25 × 30 mm erythema-
tous atrophic plaque was seen on the right precordium,
along with visible subcutaneous adipose tissue and cutane-
ous veins (Fig. 1). Three hard, smooth, and orange-
colored nodules of varying sizes were found around the
plaque. The nodules were mobile and not affixed to the
deeper structures.
Ultrasonography revealed both hyper- and hypoe-
choic tumors from the superficial dermis to the sub-
cutaneous tissue (Fig. 2a). Both lesions were ill defined
and the hypoechoic tumors were suspected to be ma-
lignant because of their abnormal hypervascularity
(Fig. 2b). Biopsy of the nodule revealed dense prolifera-
tion of spindle-shaped tumor cells from the dermis to
the subcutaneous adipose tissue; in some areas, densely
packed spindle cells were arranged in a storiform pat-
tern (Fig. 3a-c). Biopsy of the atrophic plaque showed
reduced dermal thickness and spindle cell proliferation
replaced the dermis extending into the subcutaneous
tissue (Fig. 3d-f ). Tumor cells in the elevated and atro-
phic plaques stained positive for CD34 and vimentin
and stained negative for factor XIIIa and α-smooth
muscle actin (Fig. 4).
Reverse transcription PCR (RT-PCR) of the tumor tissue
revealed gene fusion between exon 25 of COL1A1 and
exon 2 of PDGFB (Fig. 5); thus atrophic dermatofibrosar-
coma protuberans was diagnosed. Magnetic resonance im-
aging (MRI) did not reveal any metastasis to the lungs or
regional lymph nodes. A wide local excision (25–30 mm)
was performed and artificial skin was grafted. After the
resection, the stump was confirmed to be negative and
the defective area was reconstructed by split-thickness
skin grafting. Neither recurrence nor metastasis has
been observed for 5 years and 8 months since the
surgery.
DFSP, a cutaneous fibrohistiocytic tumor of intermedi-
ate malignancy [1], constitutes only 1 % of all soft-tissue
sarcomas; nonetheless, it is the most common sarcoma of
cutaneous origin [1]. It commonly occurs in individuals
20–50 years of age with an equal sex distribution [1].
DFSP is a slow growing asymptomatic tumor, and some
authors believe that many cases diagnosed in adulthood
were already present in childhood [1, 8]. In 40–50 % of
cases, DFSP preferentially occurs on the trunk, chest, and
shoulders [1]. In 30–40 % of cases, the tumor is located in
the proximal portion of the limbs; and in 10–15 % of
cases, it affects the head and neck [1]. Checketts et al. [12]
reported that congenital DFSP was predominantly located
on the trunk in 86 % of cases with a male to female ratio
of 1:2. The present case was of a woman with an atrophic
plaque on the trunk, which matched the features of con-
genital DFSP described previously.
DFSP usually appears as an indurated exophytic plaque
that protrudes above the surface of the skin. Some pa-
tients with DFSP have atrophic plaques that might be clin-
ically quiescent but have rarely been reported and
characterized in detail. The atrophic variant of DFSP was
first reported in 1985 by Lambart et al. [6] as dermatofi-
brosarcoma “non”-protuberans in a patient with the clin-
ical features of morphea and morpheaform basal cell
carcinoma. In 1987, Page and Assaad [7] reported five
additional cases with DFSP with rare clinical presentations
and proposed the term “atrophic DFSP.“ Thereafter, atro-
phic DFSP has been recognized as a distinct variant of
Fig. 1 A 25 x 30 mm erythematous atrophic plaque was seen on the right precordium, along with visible subcutaneous adipose tissue and
cutaneous veins
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DFSP, and to date, the term “atrophic DFSP“ has been
widely used [1, 2, 5, 9, 10]. Atrophic DFSP is characterized
by a depressed plaque that persists for a long period of
time before developing into a tumor. Histologically, the
dermal thickness is reduced by >50 % compared to the sur-
rounding dermis, placing the subcutis close to the epider-
mis [1]. In the present case, dermal thickness was
reduced by 30 % and tumor cells replaced the dermis
extending into the subcutaneous tissue (Fig. 6.). Immu-
nohistochemical staining for CD34 and factor XIIIa is
of great diagnostic value for DFSP. In a typical case of
DFSP, CD34 is positive in 80–100 % of cases, while
factor XIIIa is negative in 75 % of cases [1]. In the
present case, the staining pattern was typical, CD34
was positive, and factor XIIIa was negative.
Martin et al. [8] analyzed 35 previously published cases
of childhood DFSP. They presumed that the so-called
“non-protuberant” variant is one of the clinical variants
of DFSP that occurs prior to development of the indu-
rated tumor. They classified the early stage of DFSP into
four distinct variants: 1) confluent nodular lesions form-
ing a sclerotic plaque, 2) keloid-like homogenous scler-
otic plaque, 3) tumor ab initio, and 4) atrophic plaque.
Hanabusa et al. [13] reported a case of a patient who was
a
b
Fig. 2 Ultrasonography revealed both hyper- and hypo- echoic tumors from the superficial dermis to the subcutaneous tissue (a). Both lesions
were ill-defined and hypo-echoic tumors were suspected to be malignant because of their abnormal hypervascularity (b)
a b c 
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Fig. 3 Biopsy of the nodule revealed dense proliferation of spindle-shaped tumor cells from the dermis to the subcutaneous adipose tissue, and
in some areas, densely packed spindle cells were arranged in a storiform pattern (a-c). Biopsy of the atrophic plaque revealed that the thickness
of the dermis is reduced, and a spindle cell proliferation replaces the dermis extending into the subcutaneous tissue (d-f)
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initially diagnosed with morphea that subsequently devel-
oped into protuberant tumors on the face 20 years later
and was finally diagnosed with atrophic DFSP. In the
present case, the congenital atrophic plaque remained qui-
escent for more than 10 years followed by the develop-
ment of small nodules on the right precordium. This long
quiescent phase initiated the thought that the atrophic
plaque might represent an early lesion in the course of
typical DFSP.
Atrophic DFSP is a soft tissue tumor of intermediate
malignancy that has no difference in prognosis com-
pared to typical DFSP [1]. Atrophic DFSP presents as a
depressed plaque that can be clinically confused with be-
nign lesions such as morphea, atrophoderma, atrophic
scars, anetoderma, and lipoatrophy [1]. Therefore, recog-
nition of the characteristic features of atrophic DFSP is
mandatory to avoid misdiagnosis. Medallion-like der-
mal dendrocyte hamartoma (ML-DDH) is a recently
described congenital benign dermal lesion that was first
reported by Rodríguez-Jurado et al. [14] in 2004. Clin-
ical, histological, and immunohistochemical findings of
ML-DDH are very similar to those of atrophic DFSP. ML-
DDH presents as a solitary well-defined medallion-shaped
erythematous and atrophic patch located on the upper
trunk or neck that remains stable over time [13–16]. ML-
DDH is histologically characterized by a spindle cell
proliferation in the dermis and subcutaneous fat [14–17].
Furthermore, immunohistochemical staining for CD34
and factor XIIIa is usually positive and molecular testing
for COL1A1-PDGFB fusion gene is absent in ML-DDH
[14], which distinguishes ML-DDH from atrophic DFSP.
DFSP is a locally aggressive tumor with a high postsurgi-
cal recurrence rate. Surgical resection is the standard treat-
ment for DFSP; however, complete resection is sometimes
difficult because the minimum resection margin needed to
achieve local control remains undefined [1]. Local recur-
rences rates were 26–60 % when DFSP was excised with
undefined or conservative surgical margins [1]. After wide
local excision of 2–3 cm, the reported total local recurrence
rate was found to be much lower (0–30 %) [1]. When
margins of 5 cm were obtained, the recurrence rate was re-
duced to <5 % [1]. Increasingly wider margins have resulted
in lower recurrence rates; however, obtaining generous
margins is not always possible, especially when the tumors
are present on the face or neck or in children. In addition,
as the surgical margins are extended, reconstruction of the
defective area is more complex and may leave an important
cosmetic defect. DFSP is a radiosensitive disease with excel-
lent local control after conservative surgery in combination
with radiation therapy [18]. Radiation can be considered
when there is a concern about incomplete surgical resec-
tion, positive surgical margins are found after resection and
further surgery is impossible, or the lesions are >5 cm [18].
Metastasis is rare occurring in only 2–5 % of cases,
and the most common route is hematogenous dissemin-
ation to the lungs [1]. Although it is difficult to deter-
mine which cases are at risk of metastasis, cases of
metastasis generally involve recurrent lesions that have
progressed for many years and a fibrosarcomatous com-
ponent on histology [1]. Local recurrences of DFSP
mostly appear within 3 years of surgery, although late re-
currences may occur [1]. Therefore, after surgery, pa-
tients should be examined every 6 months for the first
a b
c d
Fig. 4 Tomor cells in elevated plaque revealed positive immunostaining
for CD34 (a) and vimentin (b), and negative staining for factor XIIIa (c)
and α-SMA (d)
Fig. 5 Sequencing of the multiplex RT-PCR amplification product
revealed a fusion of exon 25 of COL1A1 to exon 2 of PDGFB
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3 years and annually thereafter for life [1]. In the present
case, we performed a wide local excision (25–30 mm),
and neither recurrence nor metastasis has been observed
for 5 years and 8 months since the surgery.
Translocation of t(17;22)(q22;q13) is the cytogenetic fea-
ture of DFSP. This chromosomal rearrangement leads to
fusion of the collagen type I α1 gene (COL1A1) on 17q
with the platelet-derived growth factor β gene (PDGFB)
on 22q [1–5]. In all of the cases described to date, using
multiplex RT-PCR, the break point of PDGFB is constant
(exon 2), whereas in COL1A1, the break may occur in
any of the exons codifying the alpha-helical region
(exons 6–49) [1]. To date, 38 different COL1A1-PDGFB
fusion variants have been shown to be involved in the
pathogenesis of DFSP, with exons 25, 32, and 47 being
the most frequently involved [3]. However, no correl-
ation was found between the different COL1A1 break
points within the fusion gene and histopathological sub-
types of DFSP or the clinical characteristics [3, 4]. In the
present case, sequencing of the multiplex RT-PCR amplifi-
cation product revealed fusion of exon 25 of COL1A1 to
exon 2 of PDGFB. To our knowledge, this is the fourth
reported case of atrophic DFSP in which the COL1A1-
PDGFB fusion gene was detected: Exons 25 [2], 31 [5],
and 2 [11] of COL1A1 were previously reported to be
involved in the pathogenesis of atrophic DFSP. These
findings imply that even in atrophic DFSP, detection of
the COL1A1-PDGFB fusion gene is a powerful tool for
molecular diagnosis to differentiate other benign/malig-
nant neoplasms.
Conclusion
Here, we presented the case of a patient with congenital
atrophic DFSP with a lesion that had been recognized at
birth and remained quiescent for a long period of time
before developing into a tumor. This atrophic variant of
DFSP is believed to represent an early stage of the lesion,
and awareness of this condition can aid in early diagno-
sis and thereby improve the prognosis of DFSP.
Consent
Written informed consent was obtained from the patient
for publication of this Case Report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Abbreviations
DFSP: Dermatofibrosarcoma protuberans; RT-PCR: Reverse transcription
polymerase chain reaction; ML-DDH: Medallion-like dermal dendrocyte
hamartoma; COL1A1: The collagen type I α1 gene; PDGFB: The platelet-
derived growth factor β gene.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MM, SS, and EM looked after the patient. MM, EM, and WF wrote the report. GN
performed gene analysis. All the authors read and approved the final manuscript.
Author details
1Department of Dermatology, Kawasaki Medical School, 577 Matsushima,
Kurashiki-shi, Okayama-ken 701-0192, Japan. 2Department of Dermatology,
Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu-shi, Shiga-ken
520-2192, Japan. 3Department of Dermatology, Kawasaki Hospital, Kawasaki
Medical School, 2-1-80 Nakasange, Kita-ku, Okayama-shi, Okayama-ken,
Okayama 700-8505, Japan.
Received: 8 January 2016 Accepted: 3 February 2016
References
1. Llombart B, Serra-Guillén C, Monteagudo C, López Guerrero JA, Sanmartín
O. Dermatofibrosarcoma protuberans: a comprehensive review and update
on diagnosis and management. Semin Diagn Pathol. 2013;30:13–28.
2. Llombart B, Sanmartin O, Requena C, Monteagudo C, Botella-Estrada R,
Nagore E, Serra C, Alfaro A, Pellín A, Llombart-Bosch A, Guillén C, López-
Guerrero JA. Atrophic dermatofibrosarcoma protuberans with the fusion
gene COL1A1-PDGFB. J Eur Acad Dermatol Venereol. 2008;22:371–4.
3. Giacchero D, Maire G, Nuin PA, Berthier F, Ebran N, Carlotti A, Celerier P,
Coindre JM, Esteve E, Fraitag S, Guillot B, Ranchere-Vince D, Saiag P, Terrier P,
Lacour JP, Pedeutour F. No correlation between the molecular subtype of
COL1A1-PDGFB fusion gene and the clinic-histopathological features of
dermatofibrosarcoma protuberans. J Invest Dermatol. 2010;130:904–7.
4. Patel KU, Szado SS, Hernandez VS, Prieto VG, Abruzzo LV, Lazar AJ, López-
Terrada D. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is
identified in virtually all dermatofibrosarcoma protuberans cases when
investigated by newly developed multiplex reverse transcription polymerase
chain reaction and fluorescence in situ hybridization assays. Hum Pathol.
2008;39:184–93.
a b
Fig. 6 a: atrophic plaque, b: surrounding dermis. Dermal thickness was reduced by 30 %, and tumor cells replace the dermis extending into the
subcutaneous tissue
Makino et al. Diagnostic Pathology  (2016) 11:24 Page 5 of 6
5. Qiao J, Patel KU, Lopez-Terrada D, Fang H. Atrophic dermatofibrosarcoma
protuberans: report of a case demonstrated by detecting COL1A1-PDGFB
rearrangement. Diagn Pathol. 2012;7:166.
6. Lambert WC, Abramovits W, Gonzalez-Sevra A, Souchon E, Schwartz RA,
Little Jr WP. Dermatofibrosarcoma non-protuberans: description and report
of five cases of a morpheaform variant of dermatofibrosarcoma. J Surg
Oncol. 1985;28:7–11.
7. Page EH, Assaad DM. Atrophic dermatofibroma and dermatofibrosarcoma
protuberans. J Am Acad Dermatol. 1987;17:947–50.
8. Martin L, Combemale P, Dupin M, Chouvet B, Kanitakis J, Bouyssou-Gauthier ML,
Dubreuil G, Claudy A, Grimand PS. The atrophic variant of dermatofibrosarcoma
protuberans in childhood: a report of six cases. Br J Dermatol. 1998;139:719–25.
9. Young CRJ, Albertini MGJ. Atrophic dermatofibrosarcoma protuberans: case
report, review, and proposed molecular mechanisms. J Am Acad Dermatol.
2003;49:761–4.
10. Sheehan DJ, Madkan V, Strickling WA, Peterson CM. Atrophic
dermatofibrosarcoma protuberans: a case report and reappraisal of the
literature. Cutis. 2004;74:237–42.
11. Xu WJ, Wang JS. Atrophic dermatofibrosarcoma protuberans with the fusion
gene COL1A1-PDGFB detected by RT-PCR using only a single primer pair.
Int J Clin Exp Pathol. 2015;8:7457–63.
12. Checketts SR, Hamilton TK, Baughman RD. Congenital and childhood
dermatofibrosarcoma protuberans: a case report and review of the
literature. J Am Acad Dermatol. 2000;42:907–13.
13. Hanabusa M, Kamo R, Harada T, Ishii M. Dermatofibrosarcoma protuberans
with atrophic appearance at early stage of the tumor. J Dermatol.
2007;34:336–9.
14. Rodriguez-Jurado R, Palacios C, Durán-McKinster C, Mercadillo P,
Orozco-Covarrubias L, Saez-de-Ocariz Mdel M, Ruiz-Maldonado R.
Medallion-like dermal dendrocyte hamartoma: a new clinically and
histopathologically distinct lesion. J Am Acad Dermatol. 2004;51:359–63.
15. Marque M, Bessis D, Pedeutour F, Viseux V, Guillot B, Fraitag-Spinner S.
Medallion-like dermal dendrocyte hamartoma: the main diagnostic pitfall is
congenital atrophic dermatofibrosarcoma. Br J Dermatol. 2008;160:190–3.
16. Restano L, Fanconi D, Colonna C, Gelmetti C, Berti E. Medallion-like dermal
dendrocyte hamartoma: a case misdiagnosed as neurofibroma. Pediatr
Dermatol. 2010;27:638–42.
17. Cheon M, Jung KE, Kim HS, Lee JY, Kim HO, Park CK, Park YM. Medallion-like
dermal dendrocyte hamartoma: differential diagnosis with congenital
atrophic dermatofibrosarcoma protuberans. Ann Dermatol. 2013;25:382–4.
18. Castle KO, Guadagnolo BA, Tsai CJ, Feig BW, Zagars GK.
Dermatofibrosarcoma protuberans: long-term outcomes of 53 patients
treated with conservative surgery and radiation therapy. Int J Radiat Oncol
Biol Phys. 2013;86:585–90.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Makino et al. Diagnostic Pathology  (2016) 11:24 Page 6 of 6
